Volunteers for Alzheimer’s drug
A trial of a Melbourne-produced experimental drug, leading the race to be the world’s first treatment for early Alzheimer’s disease, is now recruiting Victorians as the research develops. The PBT2 tablet targets a naturally occurring protein in the body, called beta-amyloid.
A trial of a Melbourne-produced experimental drug, leading the race to be the world’s first treatment for early Alzheimer’s disease, is now recruiting Victorians as the research develops.
The PBT2 tablet, developed by Parkville’s Prana Biotechnology company, targets a naturally occurring protein in the body, called beta-amyloid, that turns toxic in the brain of Alzheimer’s patients.
The protein forms ‘plaque’ in the brain and “mops up” the metals that are needed for basic function.
The drug works in two ways; binding to these metals to reduce damage from proteins, but also making more metals available.
Results of the last trial showed the drug significantly reduced the amount of ‘plaque’ in the brain.
Victorians aged over 40 years with memory problems are needed for the trial. To participate, phone 1800 837 683.
